Start-Up Quarterly Statistics, Q4 2013
This article was originally published in Start Up
Executive Summary
Life science start-ups raised $1.18 billion in the final quarter of 2013, more than twice the $559.4 million they garnered in the previous quarter, and the most lucrative quarter reported for the group in the history of this START-UP column.
You may also be interested in...
Private Equity-Backed Crealta Makes Its First Move With Savient Deal
A startup called Crealta Pharmaceuticals will acquire most of Savient’s assets, including the marketed gout drug Krystexxa, for $120.4 million following a bankruptcy court auction.
CHOP Commits $50 Million To Gene Therapy Spin-Out Spark Therapeutics
Non-profit hospital spins out its first start-up, which will house one program to address a heritable form of blindness, another to treat hemophilia B.
AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability
AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.